DKSH Singapore Business Unit Healthcare broadens its portfolio in ophthalmology to support glaucoma management. The expansion reflects DKSH’s ongoing focus on unmet medical needs and patient-centered care.
Singapore, July 8, 2026 – DKSH Singapore Business Unit Healthcare announces its expansion into ophthalmology, marking a significant step in broadening its therapeutic portfolio and reinforcing its commitment to improving patient outcomes. This expansion aims to support additional treatment options for glaucoma, in response to the growing need for effective glaucoma management.
Glaucoma remains one of the leading causes of vision impairment globally and accounts for approximately 40% of blindness cases in Singapore.(1) In line with Singapore’s growing emphasis on preventive healthcare and early intervention, strengthening awareness, screening, and sustained medical management of glaucoma is critical.(2,3) While surgical interventions are available, many patients seek to optimize medical therapy prior to surgery, highlighting the importance of accessible and well-tolerated treatment options that support long-term disease control and vision preservation.(4,5).
The newly introduced ophthalmology portfolio is intended to support healthcare professionals in personalizing treatment approach and in glaucoma management, allowing clinicians to tailor treatment according to patients’ individual preferences, disease progression, and existing health conditions. The expansion aligns with current clinical practice, where long-term disease control, tolerability, and adherence are key considerations in glaucoma management. By offering additional therapeutic choices, DKSH Singapore seeks to support more personalized treatment pathways that balance efficacy with patient comfort and lifestyle needs.
“DKSH’s entry into ophthalmology reflects the company’s focus on unmet medical needs and patient-centric care,” said Reuben Ong, Vice President, Business Unit Healthcare at DKSH Singapore. “By expanding its ophthalmology portfolio, we aim to support healthcare professionals in the management of glaucoma through enabling more personalized approaches that consider patient needs, clinical factors, and long-term care objectives."
This ophthalmology expansion represents an important milestone in DKSH Singapore’s ongoing strategy to diversify its therapeutic areas. It is a testament to how the company works across the entire healthcare value chain to ensure therapies reach patients reliably, compliantly, sustainably, translating scale, local expertise, and execution discipline into tangible patient outcomes and advancing our shared commitment to Healthcare for All.
All treatment decisions should be made in consultation with qualified healthcare professionals.
About DKSH
For more than 160 years, DKSH has been delivering growth for companies in Asia Pacific, Europe, and North America across its Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, DKSH offers sourcing, market insights, marketing and sales, e-commerce, distribution and logistics as well as after-sales services, following its purpose of enriching people’s lives. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 35 markets with 26,840 specialists, generating net sales of CHF 11.1 billion in 2025. DKSH Business Unit Healthcare distributes pharmaceuticals, consumer health, over-the-counter products and medical devices. With around 7,580 specialists, the Business Unit generated net sales of CHF 5.8 billion in 2025. www.dksh.com/hec